Insilico to present latest advances in AI for Drug Discovery at The 3rd Annual SABPA FTD Forum
Anne Tseng, Head of Business Development at Insilico Taiwan, to present ‘Artificial Intelligence for Drug Discovery’ at The 3rd Annual SABPA Frontiers in Therapeutics and Diagnostics (FTD) Forum in San Diego, California
Credit: Insilico Medicine
Tuesday, January 22, 2019 – Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the 3rd Annual SABPA FTD Forum in San Diego, California, 2 of February.
Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in making the hunt for new pharmaceuticals quicker and more effective.The presentation will focus on the latest advances in artificial intelligence for discovery and development.
“We are happy to present our work at the 3rd Annual SABPA FTD Forum, which gathers the key industry leaders. The topic of AI for Drug Discovery is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in the area”, says Anne Tseng, Head of Business Development at Insilico Taiwan.
The 3rd Annual SABPA FTD Forum brings together key leaders of Gene, Cell Therapy and Artificial Intelligence industries. The speakers will share the latest breakthroughs and their visions in these areas. There will be several individual presentations and two-panel discussions focusing on CAR-T and AI, respectively. The audience will have great opportunities to ask questions, share ideas, learn from the experts, and network with their peers. The Forum is held on February 2nd, San Diego.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
For further information, images or interviews, please contact:
Contact: Polina Firsanova
Official website of the conference:
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson’s Disease, Alzheimer’s Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/